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Thymic stromal lymphopoietin (TSLP) is an epithelial
cell-derived cytokine important for the initiation and
development of T helper (Th2) cell-mediated allergic
inflammation. In this study, we identified a positive
association between interleukin-9 (IL-9) and TSLP
concentration in the serum of infants with atopic
dermatitis. In primary cell cultures, the addition of
TSLP led to an increase in IL-9 production from
human and mouse Th9 cells, and induced an
increase in signal transducer and activator of tran-
scription 5 (STAT5) activation and binding to the Il9
promoter. In vivo, use of an adoptive transfer model
demonstrated that TSLP promoted IL-9-dependent,
Th9 cell-induced allergic inflammation by acting
directly on T cells. Moreover, transgenic expression
of TSLP in the lung stimulated IL-9 production in vivo,
and anti-IL-9 treatment attenuated TSLP-induced
airway inflammation. Together, our results demon-
strate that TSLP promotes Th9 cell differentiation
and function and define a requirement for IL-9 in
TSLP-induced allergic inflammation.
INTRODUCTION
Thymic stromal lymphopoietin (TSLP) is an epithelial-derived
cytokine critical for regulating T helper 2 (Th2) cell immunity and
allergic inflammation (Al-Shami et al., 2005; Soumelis et al.,
2002; Yooet al., 2005; Zhouet al., 2005). TSLP is highly expressed
in keratinocytes of atopic dermatitis (AD) skin lesions and in asth-
matic bronchial epithelial cells (Soumelis et al., 2002; Ying et al.,
2005). TSLPtransgenicexpression inkeratinocytesor lungepithe-
lial cells results in AD-like skin inflammation or severe airway
inflammation and hyperactivity, respectively (Li et al., 2005; Yoo
et al., 2005; Zhou et al., 2005). Moreover, TSLP receptor-deficient
(Tslpr, or cytokine receptor-like factor 2 [Crlf2]) mice are protected
from developing allergic skin and lung inflammation (Al-Shami
et al., 2005; He et al., 2008; Zhou et al., 2005).
TSLP exerts its biological activities by binding to a heterodi-
meric receptor complex consisting of the interleukin-7 receptor360 Immunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc.a chain (IL-7Ra) and the TSLP receptor chain (TSLPR) (Pandey
et al., 2000; Park et al., 2000). This binding results in the
activation of signal transducer and activator of transcription 5
(STAT5) (Isaksen et al., 1999; Pandey et al., 2000; Rochman
et al., 2007, 2010). TSLP induced pathogenesis of asthma-like
airway inflammation is eliminated by genetic targeting or inhibi-
tion of IL-4 (Zhou et al., 2008), suggesting that TSLP is acting
upstream of Th2 effector cells. Indeed, TSLP induces allergic
inflammation by directly promoting Th2 cell proliferation and
Th2 cytokine production (He et al., 2008; Omori and Ziegler,
2007). TSLP also promotes dendritic cell maturation and migra-
tion to draining lymph nodes, where DC support the differentia-
tion of allergen-specific naive CD4+ T cells into Th2 cells
(Soumelis et al., 2002).
IL-9 promotes allergic inflammation and is associated with
various Th2 cell-mediated responses, including mucus produc-
tion from lung epithelial cells and pulmonary mastocytosis (Gos-
wami and Kaplan, 2011). Consistent with increased expression
of IL-9 in lungs of asthmatic patients (Erpenbeck et al., 2003;
Ying et al., 2002), overexpression of IL-9 results in asthma-like
airway inflammation and bronchial hyperresponsiveness (Te-
mann et al., 1998). In support of a pathogenic role for IL-9,
anti-IL-9 treatment inhibits airway inflammation, hyperreactivity,
and airway remodeling in mousemodels of asthma (Chang et al.,
2010; Cheng et al., 2002; Kearley et al., 2011; Kung et al., 2001).
A T helper cell subset specialized for the production of IL-9,
termed Th9 cells, is generated in the presence of transforming
growth factor-b1 (TGF-b1) and IL-4 (Dardalhon et al., 2008; Veld-
hoen et al., 2008). Th9 cells are related to Th2 cells in that they
require STAT6, GATA-3, and IRF4 for development, though
distinct from Th2 cells in their requirement for PU.1 (Chang
et al., 2010; Dardalhon et al., 2008; Goswami et al., 2012; Staudt
et al., 2010; Veldhoen et al., 2008). Th9 cells, as sources of IL-9,
contribute to allergic inflammation (Chang et al., 2010; Staudt
et al., 2010). Th9 cells differentiated from atopic patients secrete
higher amounts of IL-9 than those from nonatopic patients (Yao
et al., 2011). Furthermore, allergic donors have substantially
greater numbers of circulating Th9 cells than nonallergic donors,
and circulating numbers of Th9 cells correlate with levels of
serum IgE (Jones et al., 2012).
Although an important role for TSLP in Th2 cell differentiation
and function has been established, whether TSLP also contrib-
utes to Th9 cell-mediated inflammation, and whether IL-9 is
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IL-9 in TSLP-Mediated Inflammationrequired for TSLP-mediated inflammation, has not been defined.
In this report, we demonstrate that TSLP functions directly on
human and mouse Th9 cells to increase IL-9 production and
enhances the ability of Th9 cells to promote airway inflammation.
RESULTS
Correlation of Serum IL-9 and TSLP Concentration in
Atopic Infants
In a recent study of infants with atopic or nonatopic dermatitis,
we reported that polyclonal- or allergen-stimulated PBMCs
isolated from atopic infants (18 to 30 months old) produced
significantly higher IL-9 than non-atopic controls, although
there was no difference in the production of Th1, Th2 or
Th17 cytokines (Yao et al., 2011). To explore this further, we
measured serum cytokine concentrations in the same children
at 6-18 months of age, and one and four years later. Among
the cytokines analyzed, our data showed that atopic patients
(n = 54) showed significantly higher serum IL-9 and TSLP
than non-atopic patients (n = 25, p < 0.05) (Figure 1A). More-
over, the serum TSLP concentration positively correlated with
IL-9 concentration (r = 0.422, p < 0.05) (Figure 1B). However,
both serum IL-9 and TSLP concentrations declined with age
and decreased to low levels when the cohort reached 5 years
old, showing no significant differences between atopic and
nonatopic dermatitis patients (Figure 1C). Low concentrations
of serum IL-9 and TSLP were also observed in a separate
population of severe asthmatic adults (see Figure S1A avail-
able online), suggesting that meaningful concentrations of
these cytokines are most easily observed in young atopic
infants. These results suggest a link between TSLP and IL-9
early in atopic disease.
TSLP Promotes Th9 Cell Differentiation In Vitro
To define a functional relationship between TSLP and IL-9, naive
CD4+ T cells from PBMC of healthy donors were differentiated to
Th9 and Th2 cells in the presence or absence of 10 ng/ml human
TSLP. Significantly increased messenger RNA and protein
expression (p < 0.05) of IL-9 and IL-13 were only detected in
the respective Th9 and Th2 cell cultures in the presence of
TSLP (Figure 1D). However, TSLP did not have significant effects
on cytokine production from Th1 or Th17 cell cultures (data not
shown). Importantly, we found no significant contamination of
DCs in our purified naive CD4+ T cells (Figure S1B), further sup-
porting the conclusion that TSLP was acting directly on T cells.
TSLPR expression was greater in Th2 and Th9 cell cultures
than in Th1 and Th17 cell cultures, and TSLPR was expressed
on the surface of Th2 and Th9 cells but was at background levels
on Th1, Th17, and naive CD4 T cells (Figures 1E–G).
Next, we took advantage of mouse models to further define
the role of TSLP on Th9 cell differentiation and function in vitro
and in vivo. We found that mouse TSLP had similar effects on
Th9 and Th2 cell differentiation, increasing the IL-9+ population,
Il9 expression and IL-9 production in Th9 cell cultures, and the
IL-13+ population, Il13 expression and IL-13 protein production
in Th2 cell cultures (Figures 2A–2C). Similar results were
observed in Th2 cultures for IL-4 (data not shown). Furthermore,
TSLP enhanced IL-9 production in a dose-dependent manner
(Figure 2D).Mouse Th2 cells express higher TSLPR than Th1 and Th17
cells (Kitajima et al., 2011). Consistent with our human data (Fig-
ure 1E), we found that mouse Th9 cells expressed equivalent
amounts of Tslpr expression to Th2 cells (Figure 2E). Moreover,
TSLP treatment further induced Tslpr expression in Th9 but not
Th2 cells (Figure 2F). TSLP-induced Il9 expression was not
observed in TSLPR-deficient Th9 cell cultures (Figure 2G).
Taken together, our results show that both human and mouse
Th9 cells express TSLP receptor and that TSLP acted directly on
CD4+ T cells to promote Th9 cell differentiation and IL-9 produc-
tion in vitro.
TSLP Increases STAT5 Activation and Binding to Target
Genes
Although STAT6 activation is critical in Th9 cell differentiation,
the role of STAT5 in Th9 cell development has not been reported.
In both human and murine cells, TSLP activates STAT5 in CD4+
T cells (Omori and Ziegler, 2007; Rochman et al., 2007, 2010).
To explore TSLP-mediated STAT5 activation in Th9 cell differen-
tiation, we cultured CD4+ T cells under Th9 conditions in the
presence or absence of TSLP and assessed for intracellular
phospho-STAT5 (pSTAT5) and pSTAT6. The majority of cells
during Th9 differentiation are pSTAT6-positive, and TSLP slightly
enhanced the percentage of pSTAT6+ cells (Figure 3A; Fig-
ure S2A) (Goswami et al., 2012). TSLP had a more dramatic
effect on pSTAT5, increasing the percentage of pSTAT5-positive
early in differentiation, and increasing both the percentage of
pSTAT5-positive cells and the intensity of pSTAT5 staining later
in differentiation (Figures 3A and 3B).
To determine how STAT5 impacts IL-9 production, we tested
binding of STAT5 to the Il9 locus by chromatin immunoprecipita-
tion (ChIP). Addition of TSLP to Th9 cell cultures resulted in an
increase in STAT5 binding at two Il9 conserved noncoding
sequences (CNS1 and CNS0), compared to cultures without
TSLP (Figure 3C). Although TSLP treatment did not lead to
increases in total acetylation of histones H3 or H4, or a significant
change in H3K27 trimethylation at either conserved region, there
was an increase in acetylation of H3K9/18 at the Il9 promoter
(Figure S2B). Moreover, addition of TSLP in Th9 cell cultures
induced greater STAT5 binding to the Irf4 and Gata3 promoters
(Figure 3D), two factors required for Th9 cell development, but
not the Maf promoter (Figure S2C). Concomitantly, TSLP
enhanced Irf4 andGata3 expression (Figure 3E) but had no effect
on Maf expression (Figure S2C). Similarly, there was no change
in expression of the PU.1-encoding Sfpi1 gene (data not shown),
consistent with the induction of this gene by TGF-b signaling
pathways (Goswami et al., 2012).
TSLP also enhanced the production of IL-9 from Th9 effector
cells, following 5 days of differentiation (Figure 3F). Transient
transfection of differentiated Th9 cells with Stat5-specific small
interfering RNA (siRNA) for 24 hr significantly (p < 0.05) dimin-
ished Stat5 expression and eliminated the costimulatory effect
of TSLP on Il9 expression in Th9 cells restimulated with anti-
CD3 (Figure 3G). However, TSLP had only modest effects on
the expression of Irf4 and Gata3 in already differentiated Th9
cells and STAT5 siRNA during restimulation had only modest
effects on Irf4 and Gata3 expression (Figure S2D).
IL-2 is essential for IL-9 production by T cells (Houssiau et al.,
1995; Schmitt et al., 1994). Because both IL-2 and TSLP canImmunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc. 361
Figure 1. Relationship between TSLP and IL-9 Expression in Humans
(A–C) Serum IL-9 and TSLP in children with dermatitis. Venous blood (2 ml) was collected by venipuncture and serum was isolated. Serum IL-9 and TSLP were
measured by multiplex bead assay.
(A) Serum IL-9 and TSLP concentration of atopic dermatitis infants and nonatopic dermatitis infants (6 to 18 months old). Concentrations of IL-9 and TSLP below
detection limit were counted as zero. Atopic: n = 54; nonatopic: n = 25.
(B) Positive correlation between serum IL-9 and TSLP concentration presented in (A). Samples with IL-9 concentration below detection limit were omitted in
correlation analysis.
(C)Changesof serumIL-9andTSLPconcentrationof the samecohort ofpatients fromfirst visit (1yo,6 to18monthsold), 1-year follow-up (2yo) to5yearsofage (5yo).
(D and E) TSLP enhances human Th9 cell generation. Naive CD4+ T cells were isolated from PBMC taken from five healthy donors and differentiated to Th9 and
Th2 cells in the presence or absence of 10 ng/ml human TSLP. (D) IL-9 and IL-13 expression in Th9 and Th2 cell cultures determined by qPCR andmultiplex assay.
(E) TSLPR expression in different T helper subsets cultured in the presence or absence of 10 ng/ml human TSLP.
(F and G) TSLPR expression was determined on naive CD4 T cells and T helper cell subsets. Results are shown from one donor (F) or presented as the average
mean fluorescence intensity (background subtracted) of four donors (G).
All data are presented as the mean ± SEM. *p < 0.05. See Figure S1 for additional information.
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IL-9 in TSLP-Mediated Inflammationsignal through STAT5, we tested whether TSLP enhanced IL-9
production by inducing IL-2. Blocking IL-2 signaling with IL-2
neutralization antibody during Th9 cell differentiation resulted362 Immunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc.in a decrease in STAT5 phosphorylation (Figure 3H) and Il9
expression (Figure 3I). TSLP was able to recover partial STAT5
activation and Il9 expression, although not to the levels observed
Figure 2. TSLP Enhances Murine Th9 Cell
Generation
Mouse splenic naive CD4+ T cells were isolated
and differentiated to Th9 and Th2 cells in the
presence or absence of 10 ng/ml TSLP.
(A) Intracellular staining of IL-9-positive and IL-13-
positive population in Th9 and Th2 cell cultures
assessed by flow cytometry.
(B) Il9 and Il13 expression in Th9 and Th2 cell
cultures was determined by qPCR.
(C) ELISA analysis of IL-9 and IL-13 secreted by
Th9 and Th2 cells, respectively.
(D) Intracellular staining (left) or ELISA analysis
(right) of Th9 cell cultures incubated with in-
creasing doses of TSLP.
(E) Tslpr expression in Th subsets was determined
by qPCR.
(F) Tslpr expression in Th9 cells and Th2 cells
incubated with or without TSLP.
(G) Il9 expression in Th2 or Th9 cell cultures,
incubated with or without TSLP. Data are repre-
sentative of three to four experiments and are
presented as the mean ± SEM of at least three
replicate samples. *p < 0.05. WT, wild-type BALB/
c cells; KO, BALB/c TSLPR-deficient cells.
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a modest effect on STAT6 phosphorylation and exogenous
TSLP did not affect pSTAT6 (Figure S2E). Together, these results
suggest that STAT5 is a downstream effector in TSLP-induced
Th9 cell differentiation. TSLP can induce STAT5 phosphorylation
and IL-9 expression independently of, though it clearly cooper-
ates with, IL-2.
TSLP Enhances Th9 Cell-Mediated Allergic Airway
Inflammation
To determine the ability of TSLP to promote Th9 cell-mediated
allergic lung inflammation in vivo, we adoptively transferred Th2
or Th9 cells differentiated from DO11.10 mice to BALB/c mice
and intranasally (i.n.) challenged the recipient mice with OVA or
OVA+TSLP for 5 days. Intracellular staining and ELISA analyses
confirmed the differentiated cells had the characteristics of
Th2 (high IL-13, low IL-9) or Th9 cells (high IL-9, low IL-13) (Fig-Immunity 38, 360–372,ures 4A andB). After challenge, recipients
of either Th2 or Th9 cells developed
airway inflammation, and TSLP further
increased inflammation (Figure 4C). TSLP
was particularly effective at enhancing
Th9 cell-mediated eosinophilia in the
bronchoalveolar lavage (BAL) (Figure 4C).
To evaluate the stability of Th9 cells after
transfer and challenge, we analyzed cyto-
kine expression by DO11.10 CD4+ T cells
in the BAL from Th9 cell recipient mice.
We found that the KJ1.26+ cells main-
tained a higher percentage of IL-9+ cells
than IL-13+ cells, and TSLP attenuated
the loss of cytokine expression observed
between transfer and harvest (Figure 4D).
OVA+TSLPchallenge inducedmore IL-13and IL-9 in BAL from recipients of Th2 or Th9 cells, compared
with OVA-challenged mice. However, TSLP had greater effects
on the induction of IL-13 in Th2 cell recipients and IL-9 in Th9
cell recipients than in mice receiving the reciprocal cells (Fig-
ure 4E). Histological analysis of lungs demonstrated that TSLP
had a modest effect on peribronchial infiltration in Th2 cell
recipients, but greatly enhanced airway inflammation in Th9 cell
recipients (Figure 4F). Mucus production in both recipients of
Th2 and Th9 cells was increased by TSLP (Figure 4G). Thus,
TSLP effectively promotes Th9 cell-mediated allergic airway
inflammation, with some parameters of inflammation showing
greater TSLP-mediated effects than on Th2 cells.
TSLP-Enhanced Allergic Airway Inflammation
Requires IL-9
Because OVA+TSLP-challenged Th9 cell-recipient mice also
had increased concentrations of IL-13 in BALF (Figure 4E),February 21, 2013 ª2013 Elsevier Inc. 363
Figure 3. Enhanced STAT5 Function in TSLP-Treated Th9 Cells
(A andB) NaiveCD4+ T cells were activatedwith anti-CD3 and anti-CD28 and cultured in IL-4, TGF-b, and anti-IFN-g (Th9 cell conditions) with or without TSLP. On
day 0, 1, 3, and 5 during differentiation, cells were stained for intracellular phospho-STAT6 (pSTAT6) and phospho-STAT5 (pSTAT5).
(A) Dot plots of intracellular staining. Numbers in flow cytometry dot plots indicate the percentages of cells in each quadrant. (B) The percentages of pSTAT5+ cells
and the intensity (mean fluorescence intensity, MFI) of pSTAT5 staining is represented as the mean ± SEM.
(C–E) Naive CD4+ T cells were cultured in Th9 conditions with or without TSLP for 24 hr.
(C) STAT5 binding to conserved noncoding sequences (CNS) of Il9 was examined by ChIP and qPCR.
(D) STAT5 binding to the promoters of the indicated genes was evaluated by ChIP and qPCR.
(legend continued on next page)
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IL-9 in TSLP-Mediated Inflammationwe next examined whether TSLP enhanced airway inflammation
by promoting Th2 cytokine or IL-9 expression. We transferred
OVA-specific Th9 cells into BALB/c mice, and challenged the
mice i.n. with OVA+TSLP for 5 days. On days 1, 3, and 5, mice
received i.v. injection of 10 mg anti-IL-9 or anti-IL-13 before
OVA+TSLP intranasal challenge. Neutralizing IL-9 decreased
total cell and eosinophil counts in BAL, compared to IgG2b-in-
jected mice (Figure 5A). Amounts of IL-9 and Th2 cytokines
were decreased in the BAL fluid from anti-IL-9 treated mice (Fig-
ure 5B). Consistent with a previous report that IL-9-induced
airway inflammation was dependent on IL-13 (Temann et al.,
2007), blocking IL-13 in Th9 cell recipient mice reduced airway
inflammation and Th2 cytokines, but had little effect on IL-9
protein and gene expression in the lung (Figures 5A–5C).
While OVA+TSLP challenged recipients treated with control
antibody showed severe inflammatory cell infiltration (H&E
staining) and mucus production (PAS staining), anti-IL-9
treatment greatly attenuated airway inflammation and goblet
metaplasia (Figure 5D). These data demonstrated a requirement
for IL-9 in the TSLP-enhanced, Th9-mediated allergic airway
inflammation.
Because we also detected IL-9 in recipients of Th2 cells,
we tested the requirement for individual cytokines in Th2 cell
recipients treated with anti-IL-9, anti-IL-4, anti-IL-13, or control
antibody. All three neutralizing antibodies reduced airway inflam-
mation (Figure 5E) and BAL cytokines (Figure 5F) in recipient
mice. However, Th2 cytokines concentrations were greater,
and IL-9 amounts were less in BAL from Th2 cell recipient
mice than from recipients of Th9 cells. The fact that anti-IL-9
can diminish airway inflammation in Th2 cell recipient mice
suggests that even the low amounts of IL-9 found in these
mice are important for inflammation.
TSLP Acts Directly on Th9 Cells to Enhance Their
Function In Vivo
The ability of TSLP to enhance Th9-mediated allergic lung
inflammation in the transfer model could be through direct
effects of TSLP on Th9 cells, or on other TSLP-responsive
cells in the lung environment. TSLP can have direct effects
on Th9 development (Figure 2) and by enhancing TCR-stimu-
lated IL-9 production from Th9 effector cells (Figure 3F). To
evaluate whether TSLP acted directly on Th9 cells in vivo,
we transferred OVA-specific Th2 or Th9 cells into Tslpr/
recipient mice followed by OVA or OVA+TSLP challenge for
5 days. Compared to PBS injected control mice, both Th2
and Th9 cell recipient mice showed increased inflammatory
cellular infiltrates in BAL, and the presence of TSLP further
elevated total cell and eosinophil counts in BAL (Figure 6A).(E) Gene expression of Irf4 and Gata3 was determined using qPCR.
(F and G) Naive CD4+ T cells were cultured in Th9 conditions without TSLP.
(F) Th9 cells were restimulated with anti-CD3 in the presence or absence of TSL
(G) Th9 cells were transfected with Stat5 siRNA or control siRNA (Ctrl) and rest
expression were determined by qRCR.
(H and I) Naive CD4+ T cells were cultured in Th9 conditions with TSLP or withou
(H) The percentage of pSTAT5+ cells were determined by intracellular staining an
(I) Relative Il9 expression was evaluated by qPCR.
Data are representative of two to four experiments and are presented as themean
for additional information.Further analysis of cytokines in BAL fluid demonstrated that
increased Th2 cytokines were seen in recipients of either
Th2 or Th9 cells after OVA+TSLP challenge, whereas en-
hanced IL-9 expression was only seen in mice that received
Th9 cells (Figure 6B). Similar to wild-type BALB/c recipient
mice (Figure 4), OVA+TSLP challenge resulted in exacerbated
lung inflammatory cell infiltration and mucus production in
both Th2 and Th9 cell recipient mice, even though recipients
were deficient in TSLPR (Figure 6C). These data indicate
that TSLP increased cytokine expression in Th2 and Th9 cells
by acting directly on T cells.
IL-9 Is Required for TSLP-Induced Airway Inflammation
In Vivo
Lung-specific TSLP transgenic mice (SPC-TSLP mice) develop
spontaneous allergic airway inflammation with increased Th2
cytokines, serum IgE, and airway eosinophilia (Zhou et al.,
2005). Considering the ability of TSLP to promote Th9 differenti-
ation and function, we next wanted to determine whether IL-9 is
required for TSLP-induced airway inflammation. In addition to
airway leukocyte infiltration (Figure 7A) and increased Th2 cyto-
kines (Zhou et al., 2005), the SPC-TSLP mice showed increased
Il9 expression by BAL cells and IL-9 concentration in BAL fluid
(Figure 7B), compared to littermate control mice. Similarly,
anti-CD3-stimulated lung-draining mediastinal lymph node cells
from SPC-TSLP mice had greater numbers of Th9 cells and
expression of IL-9, compared to nontransgenic controls
(Figure 7C).
To examine whether the increased IL-9 production contrib-
uted to airway inflammation in SPC-TSLP mice, transgenic and
littermate control mice were treated with 10 mg/mouse anti-IL-
9, 50 mg/mouse anti-IL-4, or control antibodies intravenously
twice a week for 4 weeks beginning at 6 weeks of age, when
the transgenic mice began to develop airway inflammation. We
observed that pulmonary inflammation, assessed by total cell
number and by number of eosinophils and lymphocytes in the
BAL, was decreased in the anti-IL-9 treated SPC-TSLP mice,
compared to IgG2b control antibody treated mice (Figure 7D).
Amounts of IL-9 and IL-4 were decreased in the BAL fluid after
anti-IL-9 treatment in SPC-TSLP mice (Figure 7E). Blocking IL-
4 signaling not only reduced airway inflammation as we have
previously shown (Zhou et al., 2008) but also dramatically
decreased BAL IL-9 concentration as would be expected from
the role of IL-4 in Th9 generation (Figure 7E). Histopathological
analysis confirmed that anti-IL-9 treatment attenuated lung
inflammation with decreased peribronchial and perivascular
accumulation of eosinophils and lymphocytes (Figure 7F). Taken
together, lung-specific TSLP overexpression induced IL-9P and IL-9 production was evaluated by ELISA.
ed for 24 hr. Cells were restimulated with anti-CD3 and relative Stat5 and Il9
t TSLP (Ctrl), and in the presence or absence of IL-2 neutralizing antibody.
d flow cytometry.
± SEMof at least three replicate samples. *p < 0.05. See Figure S2 and Table S1
Immunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc. 365
Figure 4. TSLP Exacerbates Th9 Cell-Medi-
ated Allergic Inflammation
(A) Naive CD4+ T cells from DO11.10 mice were
differentiated under Th2 and Th9 conditions with
OVA323–339 peptide and APC. Before transfer, IL-
13+ and IL-9+ cells weremeasured in DO11.10 Th2
and Th9 cell cultures by intracellular cytokine
staining following stimulation with PMA/ion-
omycin.
(B) Concentration of accumulating IL-13 and IL-9
during Th2 and Th9 cell differentiation of DO11.10
T cells was detected using ELISA.
(C–G) Differentiated Th cells were injected to wild-
type recipients via tail vein, with PBS injection as
control. Mice were analyzed after OVA or OVA+
TSLP challenge for 5 days. After 5 days, recipient
mice were analyzed for (C) BAL total cell and
eosinophil counts, (D) percentage of IL-9+ and IL-
13+ Th9 cells before transfer and in the BAL of
recipient mice of Th9 cells, and (E) BAL cytokine
concentration by ELISA. Lung pathology was
examined by staining with (F) hematoxylin and
eosin (H&E) and (G) Periodic acid-Schiff (PAS).
All data represent mean ± SEM (n = 6–7 mice)
and are representative of at least two experiments.
*p < 0.05.
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inflammation.
The transcription factor PU.1, encoded by Sfpi1 gene, is
required for the development of Th9 cells, but not Th2 cells
(Chang et al., 2010). To delineate the contribution of Th9 cells
in TSLP-dependent airway inflammation, we adapted a model366 Immunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc.where mice were treated intranasally
with OVA and TSLP every other day
for 2 weeks (Headley et al., 2009; Lei
et al., 2011). In this TSLP-induced acute
model, neutralization of IL-9 and IL-4
reduced airway inflammation and eosin-
ophilia (Figure 7G). The coadministration
of OVA and TSLP, but not OVA alone,
stimulates airway inflammation and
cytokine expression (Figure 7H).
However, in mice with a conditional
deletion of PU.1 in T cells (Sfpi1lck/
mice) airway inflammation (Figure 7H)
and cytokine expression in the lung
were diminished (Figure 7I). Thus, Th9
cells are required for TSLP-induced
allergic inflammation.
DISCUSSION
TSLP plays important roles in regulating
Th2 cell-mediated immunity and allergic
diseases (Zhang and Zhou, 2012). TSLP
functions by stimulating multiple cell
types including dendritic cells, epithelial
cells, and mast cells (Allakhverdi et al.,
2007; Fontenot et al., 2009; Ito et al.,2005; Semlali et al., 2010; Soumelis et al., 2002; Wang
et al., 2006). In addition, TSLP, in conjunction with TCR stimula-
tion, can act directly on naive CD4+ T cells to promote cell prolif-
eration and Th2 differentiation (Omori and Ziegler, 2007; Roch-
man et al., 2007; Sokol et al., 2008) while suppressing Treg
differentiation (Lei et al., 2011). In this study, we report that
Figure 5. IL-9 Is Required for TSLP Aug-
mented Allergic Airway Inflammation in
Recipients of Th9 and Th2 Cells
(A–D) Differentiated DO11.10 Th9 cells were
transferred to recipient mice as described in Fig-
ure 5. During challenge (OVA + TSLP), 10 mg/
mouse anti-IL-9, anti-IL-13 or IgG2b control mAb
was administrated via tail vain injection on days 1,
3, and 5. Mice were analyzed 24 hr after the last
treatment for (A) total cell and differential cell
counts in BAL, (B) BAL cytokine concentration by
multiplex bead assay, (C) Il9 and Il13 expression in
lungs by qPCR, and (D) tissue pathology by
Hematoxylin and eosin (H&E) and Periodic acid-
Schiff (PAS) staining of paraffin-embedded lung
sections.
(E and F) Differentiated DO11.10 Th2 cells were
transferred to recipient mice. During challenge
(OVA + TSLP), 10 mg/mouse anti-IL-9, anti-IL-13,
or 50 mg/mouse anti-IL-4 mAb was administrated
via tail vain injection on days 1, 3, and 5. Control
mice received IgG2b control mAb. Mice were
analyzed 24 hr after the last treatment for (E) total
cell and differential cell counts in BAL, and (F) BAL
cytokine concentration by multiplex bead assay.
All data represent mean ± SEM (n = 5 mice) and
are representative of at least two experiments.
*p < 0.05. E, eosinophils; N, neutrophils; M,
macrophages; L, lymphocytes.
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IL-9 in TSLP-Mediated InflammationTSLP acts on both human and mouse CD4+ T cells to promote
Th9 differentiation and function. On the basis of data correlating
TSLP and IL-9 serum levels in atopic infants, we tested the
requirement for IL-9 in models of allergic inflammation. Neutral-
izing IL-9 attenuated SPC-TSLP transgene- and OVA+TSLP-
induced allergic airway inflammation. TSLP and IL-9 have
already been shown to be required in several models of allergic
inflammation, including the OVA/alum and papain models
(Al-Shami et al., 2005; Chang et al., 2010; Cheng et al., 2002;Immunity 38, 360–372,He et al., 2008; Kung et al., 2001; Wilhelm
et al., 2011; Zhou et al., 2005). Our data
now establishes that Th9 cells are an
indispensable component of TSLP-medi-
ated allergic inflammation.
STAT proteins are critical promoters
of T helper cell differentiation, with indi-
vidual or combinations of STAT proteins
required for specific lineages (Stritesky
and Kaplan, 2011). Th2 and Th9 cells
require STAT6, although STAT3 is
required for Th2 but not Th9 cell devel-
opment (Dardalhon et al., 2008; Gos-
wami et al., 2012; Stritesky et al.,
2011; Veldhoen et al., 2008). STAT5
activation also plays an important role
in Th2 cell differentiation, and a constitu-
tively active STAT5 can induce Th2 cell
differentiation independent of IL-4 and
STAT6 (Zhu et al., 2003). STAT5 binds
to multiple cytokine genes including
Th2 cytokines and Il9 (Cote-Sierraet al., 2004; Fung et al., 2005; Liao et al., 2008). This is consis-
tent with our observations that STAT5 binds directly to the Il9
locus in Th9 cells. Moreover, reducing Stat5 expression elimi-
nated the ability of TSLP to enhance anti-CD3-induced Il9
expression. STAT5 may additionally promote Th9 development
by binding to genes encoding other transcription factors
required for Th9 development, including Irf4 and Gata3. Th9
development is also dependent upon IL-2 (Houssiau et al.,
1995; Schmitt et al., 1994), and IL-2 is clearly responsible forFebruary 21, 2013 ª2013 Elsevier Inc. 367
Figure 6. TSLP Acts Directly on Transferred Th9 Cells to Enhance Effector Function
TSLP enhanced Th9 effector function in vivo. Naive CD4+ T cells from DO11.10 mice were differentiated under Th2 and Th9 skewed conditions with OVA323–339
peptide and APC. Differentiated Th cells were injected to Tslpr/ recipients via tail vein, with PBS injection as control. Mice were analyzed after challenge with
OVA or OVA+TSLP for 5 days for (A) BAL total cell and eosinophil counts, (B) BAL cytokine concentration using ELISA, and (C) tissue pathology using hematoxylin
and eosin (H&E) and Periodic acid-Schiff (PAS) staining of paraffin-embedded lung sections.
All data represent mean ± SEM (n = 5) and are representative of two experiments. *p < 0.05.
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Figure 7. IL-9 Is Required for Maximal TSLP-Induced Airway Inflammation in TSLP-Induced Chronic and Acute Airway Inflammation
(A–C) BAL fluid, lung tissue, and lung-draining mediastinal lymph nodes were collected from 6-month-old SPC-TSLP transgenic mice (Tg) and littermate controls
(WT) andanalyzed for (A) cell number in theBALof transgenic and littermatecontrolmice (B) Il9geneexpression inBALcells and IL-9present in theBALfluid, and (C)
IL-9 production by mDLN cells following stimulation with PMA/ionomycin (intracellular staining, left), or anti-CD3 stimulation (qPCR and ELISA, meddle and right).
(D–F) Neutralization of IL-9 in SPC-TSLP transgenic mice. Anti-IL-9 (10 mg/mouse), anti-IL-13 (10 mg/mouse), anti-IL-4 (50mg/mouse), or IgG2b isotype control
(10 mg/mouse) were injected to SPC-TSLP and littermate control mice via tail vein twice a week for 4 weeks starting at 6 weeks of age. At 10 weeks of age, mice
were analyzed for (D) total and differential cell counts in the BAL, (E) cytokine concentration in the BAL, and (F) lung histology by hematoxylin and eosin (H&E).WT,
littermate controls; Tg, SPC-TSLP transgenic mice.
(G) Neutralization of IL-9 in TSLP-induced acute airway inflammation. BALB/cmice were treated intranasally every other day with 50 mg OVA and 500 ng TSLP for
2 weeks. Anti-IL-9 (10 mg/mouse), anti-IL-4 (50mg/mouse), or IgG2b isotype control were injected i.v. 30 min. before OVA+TSLP treatment. Total and differential
cell counts in the BAL were analyzed 24 hr after the last treatment.
(H and I) Role of Th9 cells in TSLP-induced acute airway inflammation. C57BL/6 and Sfpi1lck/mice were treated with OVA+TSLP as described in (G). Control
group were C57BL/6 mice receiving OVA alone. Twenty-four hours after the last treatment, mice were analyzed for (H) total and differential cell counts in the BAL
and (I) cytokine gene expression in the lung by qPCR.
All data represent mean ± SEM (n = 4–6 mice) and are representative of at least two separate experiments. *p < 0.05. E, eosinophils; N, neutrophils;
M, macrophages; L, lymphocytes.
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IL-9 in TSLP-Mediated Inflammationa proportion of pSTAT5 in developing Th9 cells. TSLP was
capable of activating STAT5 and inducing IL-9 when IL-2 was
blocked, suggesting that TSLP can function independently of
IL-2. However, there is clearly an additive effect when cells are
exposed to both cytokines. Thus, our data suggest that STAT5
contributes to Th9 differentiation and that it serves as an impor-
tant conduit between TSLP stimulation and IL-9 production.
TSLP enhances the differentiation of Th2 and Th9 cells derived
from either human or mouse naive CD4 T cells. Recent studies
reported that Th2 cells expressed more TSLPR than Th1 or
Th17 cells (Kitajima et al., 2011), and TSLP was critical for
antigen-induced Th2 cytokine secretion by skin-infiltrating Th2
effectors in an atopic dermatitis model (He et al., 2008). We
found that both human and mouse Th9 cells expressed TSLP
receptor chain similar to Th2 cells, and inmouse cells expression
was further amplified by TSLP stimulation. Thus, Th9 effectors
might be a critical TSLP responsive cell type. Indeed, TSLP
doubled IL-9 production from anti-CD3 stimulated Th9 cells
and from in vivo effectors. Thus, TSLP likely contributes to
both differentiation and effector function of Th9 cells.
The development of allergic inflammation in the lung requires
the cooperation of Th2 and Th9 cells. The division of labor
between these subsets is still unclear. Previous experiments
have suggested that IL-9 promotes type 2 cytokine production
by innate lymphoid cells in the lung (Wilhelm et al., 2011) and
IL-13-deficiency inhibits the allergic inflammation initiated by
an IL-9 transgene (Temann et al., 2007). This was recapitulated
in our studies showing that blockade of IL-13 diminished inflam-
mation in Th9 cell recipient mice. Conversely however, blockade
of IL-9 inhibited the development of inflammation in recipients of
Th2 cells. This is consistent with the requirement for Th9 cells,
established using mice with PU.1-deficient T cells, in models of
allergic airway inflammation, even when Th2 cell development
is normal (Chang et al., 2010). Thus, it is difficult to develop an
ordered model of Th9 and Th2 cell function, and each subset
likely contributes parallel but overlapping functionality in the
development of allergic inflammation.
In summary, we have elucidated a mechanism of TSLP-medi-
ated allergic airway inflammation through enhancing Th9 cell
differentiation and IL-9 production. This function of TSLP is
conserved between human and murine T helper cells. Together
with the action of TSLP on Th2 cell differentiation, our data pro-
vide insight into the ability of TSLP to promote allergic disease.
Given that both TSLP and Th9 cells are required for other types
of inflammation (Jabeen and Kaplan, 2012; Zhang and Zhou,
2012), it will be important to establish whether the link between
TSLP and IL-9 is important for additional human diseases.
EXPERIMENTAL PROCEDURES
Human Subjects
Children with chronic dermatitis (n = 116) recruited for this study have
previously been described (Tepper et al., 2008). Subjects were excluded
for a history of prior wheezing, lower respiratory tract illness, treatment
with asthma medications, or congenital heart disease. Patient sample collec-
tion and analysis were approved by the Institutional Review Board of Indiana
University and required parental consent for samples from infants.
Mice
BALB/c, C57BL/6, and DO11.10 TCR transgenic mice were purchased from
Jackson Laboratories. Spfi1-conditional mutant mice, Tslpr mutant (Tslpr/)370 Immunity 38, 360–372, February 21, 2013 ª2013 Elsevier Inc.mice, and SPC-TSLP transgenic mice were described previously (Dakic
et al., 2005; Zhou et al., 2005). All mice were housed in specific pathogen-
free conditions, and all experiments were performed as approved by the
IACUC.
Multiplex Analysis of Patient Serum Cytokines
Venous blood (2 ml) was collected by venipuncture and serum was isolated.
Patients were defined as atopic on the basis of positive allergen-specific
serum IgE as described previously (Tepper et al., 2008; Yao et al., 2010,
2011). The concentration of IL-9 and TSLP in the serum was measured with
theMilliplexMAP Kit according to themanufacturer’s protocol (Millipore) using
a Luminex 200 system (Luminex) for data acquisition and analysis. Cytokine
concentrations were calculated with Bio-Plex Manager 2.3 software with
a five-parameter curve-fitting algorithm applied for standard-curve
calculations.
Quantitative RT-PCR
Total RNA was isolated from anti-CD3 (2 mg/ml)-restimulated cells with Trizol
and reverse transcribed according to manufacturer’s instructions (Invitrogen
Life Technologies, Carlsbad, CA). Quantitative PCR was performed with Taq-
man Fast Universal PCR Master Mix and commercially available primers for
genes with the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster
City, CA). RNA was normalized to expression levels of b2-microglobulin and
relative expression was calculated by the change-in-threshold (DDCT)
method.
Helper T Cell Differentiation
Human and mouse Th cell differentiation was performed as described (Chang
et al., 2010; Yao et al., 2011). After 5–6 days of culture, differentiated cells were
restimulated for 24 hr with plate-bound anti-CD3 (2 mg/ml), and cell-free
supernatants were collected after centrifugation were stored at 20C for
measuring cytokine production. In some experiments, cell pellets were
collected after 6 hr of restimulation for RNA extraction. TSLPR expression
was examined by flow cytometry (Biolegend).
Naive OVA-specific CD4+ T cells from DO11.10 mice were purified from
spleens and lymph nodes as described above and were stimulated with
10 mg/ml OVA323–329 peptide and mitomycin-treated, CD4
+ T cell-depleted
APCs (1:5) in the presence of anti-CD28 (0.5 mg/ml), anti-IFN-g (10 mg/ml),
and IL-4 (10 ng/ml), without (Th2 cell differentiation) or with 2 ng/ml TGF- b1
(Th9 cell differentiation). On day 3 of culture, cells were expanded by adding
half the dose of the original cytokines in fresh medium. After 5 days of culture,
differentiated cells were analyzed by intracellular staining before adoptive
transfer.
Intracellular Staining
After restimulation with anti-CD3 (4 mg/ml) for 5 hr, monensin was added to the
cells for the final 2 hr of stimulation. Cells were fixed with 4% neutral buffered
paraformaldehyde and permeabilized with saponin. Cells were then stained
with fluorochrome-conjugated anti-mouse IL-9, IL-13, CD4, and KJ1.26 (eBio-
science). For intracellular phospho-STAT staining, T cells were collected and
fixed with 1.5% formaldehyde for 10 min at room temperature. After fixation,
cells were permeabilized for 15 min at 4C with 100% methanol. Cells were
then stained for phospho-STAT5 or phospho-STAT6 (BD PharMingen) for
30 min at room temperature.
Chromatin Immunoprecipitation
ChIP assay was performed as previously described (Yu et al., 2007). Immu-
noprecipitations were performed with rabbit polyclonal antibodies (rabbit
control IgG [Santa Cruz], AcH3, AcH4, AcH3K9-18, and H3K27me3 [Upstate])
or mouse monoclonal antibodies (mouse IgG and anti-Stat5a/b [Upstate]).
Quantification of binding DNA was performed with SYBR Green Fast PCR
Master Mix (see Table S1 for primer sequences) via ABI 7500 fast real-time
PCR System. To quantify immunoprecipitated DNA, we generated a standard
curve from serial dilutions of input DNA. To calculate ChIP results as
a percentage of input, we subtracted the amount of the immunoprecipitated
DNA from the IgG control from the amount of the immunoprecipitated DNA
from the specific antibody ChIP followed by normalizing against the amount
of the input DNA.
Immunity
IL-9 in TSLP-Mediated InflammationsiRNA Silencing of STAT5
Th9 cells were transfected with control or Stat5-specific siRNA (Santa Cruz
Biotechnology) with aMouse TCell Nucleofector kit according to themanufac-
turer’s instructions (Amaxa Biosystems). T cells (5 3 106) were suspended in
Mouse T cell Nucleofector Solution and were transfected with 1 mg siRNA
using the X-001 transfection program (Amaxa). Transfected cells were plated
in prewarmed culture media at 37C. After resting for 24 hr, cells were stimu-
lated and RNA was collected for quantitative PCR.
Adoptive Transfer Experiments and Cytokine Neutralization
Differentiated OVA-specific Th2 or Th9 cells (2–3 3 106 T cells in 200 ml PBS)
were adoptively transferred into wild-type or Tslpr-deficient recipient mice via
tail-vein injection. Twenty-four hours after cell transfer, mice were challenged
i.n. with 100 mg OVA or 100 mg OVA plus 500 ng TSLP for 5 days. Mice were
then sacrificed 24 hr after last challenge for further analysis.
To neutralize cytokine in recipients of Th2 or Th9 cells, we injected mice
via tail vein with anti-IL-9 (10 mg/dose), anti-IL-4 (50 mg/dose), anti-IL-13
(10 mg/dose), or IgG2b control Ab (10 mg/dose, R&D Systems) on days 1, 3,
and 5. To neutralize cytokines in SPC-TSLP transgenic mice, anti-IL-9
(10 mg/dose), anti-IL-4 (50 mg/dose), or IgG2b control Ab (10 mg/dose) were
injected via tail vein twice a week for 4 weeks from 6 weeks of age. Mice
were sacrificed 24 hr after last injection for further analysis.
Bronchoalveolar Lavage, Tissue Fixation, and Staining
Mice were euthanized, and bronchoalveolar lavage (BAL) was performed as
described previously (Lei et al., 2011). Briefly, lungs were washed three times
with cold PBS. BAL fluid fractions were centrifuged at 1400 3 g for 5 min at
4C. Pellets were resuspended and counted. Cytospin preparations were
stained with modified Wright-Giemsa stain, and differential cell counts were
evaluated by counting at least 200 cells for determination of relative
percentage of each cell type in the BAL. The cytokine levels in BAL fluid
were assessed by ELISA or Multiplex assay as indicated. After lavage, lungs
were excised from thorax cavity, inflated with 4% neutral buffered formalde-
hyde, and fixed overnight at room temperature. Tissues were embedded in
paraffin, sectioned, and stained with H&E or periodic acid-Schiff (PAS) stain.
Isolation and Restimulation of Cells from Lung Draining Lymph
Nodes
Mediastinal draining lymph nodes were dissected from sensitized and
challenged mice, and single-cell suspensions were prepared before stimula-
tion in vitro with plate-bound 2 mg/ml anti-CD3 (17A2; Biolegend) for 72 hr.
Cytokine levels in cell-free supernatants were measured using ELISA. The
amount of IL-9 produced was determined by ELISA with anti-IL-9 (D8402E8;
BD Biosciences) as the capture antibody and biotin-labeled anti-IL-9
(D9302C12; BioLegend) as the secondary antibody.
Data and Statistical Analysis
Data are presented as mean ± SEM. ANOVA with Bonferroni posttests and
Student t test were performed with Prism version 4.00 (GraphPad). Spear-
man’s correlation was performed on serum cytokine values, excluding
samples where either cytokine was undetectable in multiplex assays.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and one table and can be found
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